Track topics on Twitter Track topics that are important to you
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.
InterCure, a medical device company has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases. The Company has incorporated its "Interac...
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www...
We have published hundreds of InterCure Ltd. news stories on BioPortfolio along with dozens of InterCure Ltd. Clinical Trials and PubMed Articles about InterCure Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of InterCure Ltd. Companies in our database. You can also find out about relevant InterCure Ltd. Drugs and Medications on this site too.
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...